Tarsus Pharmaceuticals (NASDAQ:TARS) Stock Price Expected to Rise, Barclays Analyst Says

Tarsus Pharmaceuticals (NASDAQ:TARS) had its price target upped by research analysts at Barclays from $60.00 to $62.00 in a research note issued on Monday,Benzinga reports. The brokerage presently has an “overweight” rating on the stock. Barclays‘s target price indicates a potential upside of 21.43% from the company’s previous close.

Several other brokerages have also commented on TARS. The Goldman Sachs Group increased their price objective on shares of Tarsus Pharmaceuticals from $36.00 to $41.00 and gave the company a “neutral” rating in a research report on Friday, November 15th. Oppenheimer raised their price target on shares of Tarsus Pharmaceuticals from $65.00 to $72.00 and gave the stock an “outperform” rating in a report on Wednesday, January 22nd. One investment analyst has rated the stock with a hold rating, four have given a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, Tarsus Pharmaceuticals presently has a consensus rating of “Buy” and a consensus target price of $56.00.

Tarsus Pharmaceuticals Stock Down 0.8 %

NASDAQ:TARS opened at $51.06 on Monday. The company has a debt-to-equity ratio of 0.30, a quick ratio of 5.38 and a current ratio of 5.42. The stock has a market capitalization of $1.95 billion, a P/E ratio of -13.40 and a beta of 1.02. The company’s 50-day simple moving average is $51.26 and its 200-day simple moving average is $39.40. Tarsus Pharmaceuticals has a fifty-two week low of $20.08 and a fifty-two week high of $57.14.

Institutional Trading of Tarsus Pharmaceuticals

A number of hedge funds and other institutional investors have recently made changes to their positions in TARS. R Squared Ltd purchased a new position in shares of Tarsus Pharmaceuticals during the 4th quarter valued at about $53,000. FMR LLC lifted its holdings in Tarsus Pharmaceuticals by 236.6% in the third quarter. FMR LLC now owns 5,032 shares of the company’s stock valued at $166,000 after acquiring an additional 3,537 shares during the period. Dark Forest Capital Management LP acquired a new position in Tarsus Pharmaceuticals in the second quarter valued at approximately $202,000. SG Americas Securities LLC boosted its position in Tarsus Pharmaceuticals by 87.5% in the 3rd quarter. SG Americas Securities LLC now owns 7,242 shares of the company’s stock worth $238,000 after purchasing an additional 3,379 shares in the last quarter. Finally, China Universal Asset Management Co. Ltd. increased its holdings in shares of Tarsus Pharmaceuticals by 64.9% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 7,317 shares of the company’s stock valued at $241,000 after purchasing an additional 2,879 shares in the last quarter. Institutional investors and hedge funds own 90.01% of the company’s stock.

Tarsus Pharmaceuticals Company Profile

Tarsus Pharmaceuticals, Inc, a commercial stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease.